The Merck & Co drug’s failure in small-cell lung cancer prompts a theory and leaves the way clear for Roche and Astrazeneca.
The most important clinical readouts of the holiday period concerned Google Health, Axsome, Wave and Spectrum.
An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.
The presentation of Biogen’s hugely complex aducanumab pivotal programme confirms that the US regulator is destined to make another polarising decision.
As a phase III blow-up brings Sage Therapeutics’ run of success to an end, the company’s post-hoc analyses fail to reassure investors that its depression project has a…
Twin setbacks for grass pollen allergy projects in development by Asit Biotech and Allergy Therapeutics expose an existential crisis.
The healthcare company builder Puretech registers one success and one failure, both underlining the need for robust mid-stage data.
Supernus needs something to fill the gap left by its faltering epilepsy drug Trokendi XR, but SPN-810 isn’t it.
An advisory panel votes to pull Amag’s Makena from the market, but will the US regulator follow through?